No less interesting is the fact that a positive PD-L1 expression in the tumor center and the invading tumor front— as well as as PD-L1 level > 793 ng/mL—leads to a worse overall survival rate in CCRCC patients. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.